CYP3A5 expression is regulated by single-nucleotide polymorphisms (SNPs). The CYP3A5 genotype might contribute to a marked interindividual variation in CYP3A-mediated metabolism of drugs. Nifedipine is a typical substrate of CYP3A4 and CYP3A5 in vitro. The aim of this study was to elucidate the influence of the CYP3A5 genotype on nifedipine disposition in healthy subjects. A single capsule containing 10 mg of nifedipine was administered to 16 healthy male Japanese subjects (eight subjects: CYP3A5*1/*3; eight subjects: CYP3A5*3/*3). Blood samples were collected to analyze the pharmacokinetics of serum nifedipine and nitropyridine metabolite (M-I). The area under the plasma concentration-time curve (AUC), the peak plasma concentration (C max ) and the terminal half-life (t 1/2 ) of nifedipine, and the ratio of the nifedipine AUC to M-I AUC showed large intragroup variations, but no significant differences between the two genotypes. Based on the present findings, the functional relevance of CYP3A5 polymorphism should be re-evaluated in clinical trials. 2 Recently, single-nucleotide polymorphisms (SNPs) were identified in intron 3 (A-G: CYP3A5*3) and exon 7 (G-A: CYP3A5*6) of the CYP3A5 gene.
INTRODUCTION
Cytochrome P450 3A (CYP3A) is abundantly expressed in human liver and small intestine, 1, 2 and contributes to the metabolism of 50% of prescribed drugs. The activities of CYP3A in the general population show interindividual variations in CYP3A-mediated metabolism of drugs. 2 Recently, single-nucleotide polymorphisms (SNPs) were identified in intron 3 (A-G: CYP3A5*3) and exon 7 (G-A: CYP3A5*6) of the CYP3A5 gene. 3 In addition, CYP3A5*5 and CYP3A5*7 were reported as a defective allele of CYP3A5, which gave a substantial impact on CYP3A5 expression. 4, 5 These SNPs cause a frame-shift mutation or alternative splicing and protein truncation, and result in the absence of CYP3A5, suggesting that only people with at least one CYP3A5*1 allele express large amounts of CYP3A5 protein. Therefore, these findings suggest that polymorphic CYP3A5 expression might be one factor contributing to the marked interindividual variation observed in CYP3A-mediated metabolism of drugs.
We previously reported the frequencies of CYP3A5-related SNPs in 200 healthy Japanese subjects. 6 As a result, the allele frequency of CYP3A5*3 was approximately 70%, but CYP3A5*6 was not detected in the Japanese population. Accordingly, these findings suggested that about 40% of Japanese express relatively high levels of metabolically active CYP3A5 protein.
To obtain clinical evidence of CYP3A5 polymorphism, we focused on nifedipine, a typical substrate of CYP3A4 and CYP3A5, [7] [8] [9] because a large individual difference was observed in nifedipine disposition, 10 which was thought to be regulated by a genetic background rather than environment. 11 Consistently, using baculovirus-expressed human CYP3A5 and CYP3A4, we confirmed their contribution to the metabolism of nifedipine (Table 1 ). These findings suggested that CYP3A5 contributes to the metabolism of nifedipine with kinetics similar to CYP3A4, implying that the interindividual differences in nifedipine disposition might be explained in part by CYP3A5 polymorphism. Thus, in the present study, we evaluated the influence of the CYP3A5 genotype on nifedipine disposition in healthy subjects to examine the polymorphic activities of CYP3A5 in vivo.
RESULTS
The subjects were genotyped and divided into two groups, CYP3A5*1/*3 and CYP3A5*3/*3 ( Table 2) . No subject had the other CYP3A5 alleles, CYP3A5*5, CYP3A5*6 and CYP3A5*7. First, the plasma concentration profiles of nifedipine and M-I were compared between *1/*3 and *3/*3 groups. Unexpectedly, the time profiles of both plasma nifedipine and M-I were not significantly different between the two genotypes ( Figure 1 ). Moreover, plasma nifedipine and M-I showed a large intragroup variation. Next, the typical pharmacokinetic parameters of nifedipine, such as the area under the plasma concentration-time curve from 0 to 12 h after administration (AUC 0-12 h ), the peak plasma concentration (C max ), terminal half-life (t 1/2 ) and clearance (CL/F) were calculated ( Table 3 ). The AUC 0-12 h values showed large intragroup variations without significant differences between the two genotypes (218.8780.9 ng h/ml in CYP3A5*1/*3 subjects, 178.7792.8 ng h/ml in CYP3A5*3/*3 subjects; mean7SD). Furthermore, the ratio of the nifedipine AUC 0-12 h to the M-I AUC(4.77 in CYP3A5*1/*3 subjects, 3.62 in CYP3A5*3/*3 subjects; mean) also showed large intragroup variations with no significant differences between the two genotypes ( Figure 2 ). The differences in the C max , t 1/2 and CL/F of nifedipine between the two groups were not significant.
Finally, we measured systolic and diastolic blood pressure and pulse rate to estimate the significance of CYP3A5 polymorphism in the pharmacodynamics of nifedipine. Consistent with the pharmacokinetics, there were no significant differences in the pharmacodynamics between the two genotypes ( Figure 3 and Table 4 ).
DISCUSSION
In the present study, we examined the effects of CYP3A5 genotype on nifedipine pharmacokinetics, and demonstrated that an interindividual variation of plasma nifedipine concentration was not over-ridden by the CYP3A5 genotype. The interindividual variation was not beyond our conception and was almost similar to that described in the previous report following the administration of a 10-mg capsule. 12 The present finding suggests that CYP3A5 polymorphism is unlikely to be responsible for interindividual variation in the plasma level of nifedipine because the remaining CYP3A5 alleles, CYP3A5*5, CYP3A5*6 and CYP3A5*7, were not found in the present subjects.
With respect to nifedipine metabolism, nifedipine disposition is slightly affected by the expression of intestinal CYP3As because grapefruit juice influences nifedipine disposition significantly but to a lesser extent than felodipine or nisoldipine, 10, 13, 14 suggesting that nifedipine is mainly metabolized not in the intestine but in the liver. In addition, it is hypothesized that P-glycoprotein (P-gp) is responsible for the large interindividual difference in Table 1 Enzyme kinetic analyses of the conversion of M-I using baculovirus-expressed human ¼ P450s CYP3A5 polymorphism and nifedipne pharmacokinetics T Fukuda et al CYP3A-mediated drug disposition, since P-gp exists in the similar tissue to CYP3A4. However, this hypothesis is not the case with nifedipine disposition because nifedipine is not a substrate of P-gp. 15, 16 Therefore, nifedipine pharmacokinetics must be crucially determined by the total liver CYP3A activities.
It was reported that nifedipine, as well as midazolam, were not only metabolized by CYP3A4 but also by CYP3A5 in vitro. [7] [8] [9] 17 Prior to clinical study, we conducted kinetic study on the formation of M-I using recombinant microsomes (CYP3A4 and CYP3A5) because previous reports provided the oxidation activity at a single high concentration of nifedipine. We confirmed the contribution of CYP3A5 toward the metabolism of nifedipine at relatively low concentrations.
We, however, observed a discrepancy between the in vitro and in vivo contribution of CYP3A5 to nifedipine metabolism in the present study. Interestingly, a similar result has been obtained in the case of midazolam, a typical CYP3A5 substrate. Namely, midazolam pharmacokinetics was also hardly influenced in vivo by the genotype of CYP3A5, 18 although midazolam is metabolized in vitro by CYP3A5 rather than CYP3A4. 3, 17, 19 Several possibilities can be proposed to explain these discrepancies between the in vitro and in vivo data.
It was previously reported that total CYP3A activity showed an interindividual variation, 2 and the ratio of CYP3A4 to CYP3A5 might also vary interindividually in the liver. 20 Recently, Westlind-Johnsson et al 21 reported that CYP3A5 did not contribute to total CYP3A activity using CYP3A5 polymorphism and nifedipne pharmacokinetics 22 Although these data seem to support the present findings in vivo, the same was not consistent in the case of midazolam. Based on all these observations, we speculated that the amount of CYP3A5 protein in the liver is much lower than CYP3A4, although we should consider the limitations of our study design. This speculation might be demonstrated by using CYP3A5-specific substrates, although no drugs metabolized specifically by CYP3A5 have been reported yet. With respect to mRNA expression, it was reported that CYP3A genes exhibit a degree of tissue-specific expression and CYP3A5 is predominantly expressed in the adrenal grand, prostate and kidney. 23 Therefore, CYP3A5 polymorphism might have a physiological and pharmacological effect, which is related to the extrahepatic tissues. This possibility remains to be verified in further studies.
Interindividual differences in nifedipine pharmacokinetics remain to be elucidated genetically. Here, we propose that polymorphic regulation of CYP3A4 gene transcription, including the polymorphisms of the promoter activities and transcriptional factors, may have to be taken into account to explain the variation of nifedipine pharmacokinetics. However, a polymorphism, which plays a significant role in the activity of CYP3A4, has not yet been identified in the 5 0 -regulatory region of the CYP3A4 gene. 24 Therefore, we have focused on human PXR (hPXR) as a factor effecting CYP3A expression and identified splicing variants of hPXR as a possible factor in interindividual variation caused in CYP3A activity. 25 Interestingly, we have found that mRNA expression of wild-type hPXR is well correlated with mRNA expression of CYP3A4 in liver sample (unpublished data), which is consistent with the recent report. 21 In summary, we revealed that nifedipine disposition in vivo is not affected by the CYP3A5*3 allele. Owing to a discrepancy between the in vitro and in vivo contribution of CYP3A5, the functional relevance of CYP3A5 in humans should be re-evaluated by clinical studies for each drug.
MATERIALS AND METHODS

In vitro Screening for the Contributions of CYP3A4 and CYP3A5
Nifedipine and phenytoin were purchased from Wako Pure Chemicals Co. (Osaka, Japan) and oxidized nifedipine (ULTRAFINE) was obtained from Funakoshi (Tokyo, Japan). Microsomes from baculovirus-infected insect cells expressing human CYP3A4 and CYP3A5 with NADPH cytochrome P450 reductase (GENTEST) were obtained from Daiichi Pure Chemicals Co. (Tokyo, Japan). NADPH was purchased from Oriental Yeast Co. (Tokyo, Japan). Other reagents and Values were the mean7SD of blood pressure changes (%). Each blood pressure change (%) was calculated by the formula ((measured-baseline)/baseline Â 100).
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T Fukuda et al organic solvents were obtained from Nakarai Tesq Chemical Industries (Kyoto, Japan). All incubation, extraction and other handling of samples were carried out in amber vials. A mixture (0.50 ml) containing 10 pmol of P450 protein from baculovirusexpressed human CYP3A4 and CYP3A5 and 1 mM NADPH in 0.1 M potassium phosphate buffer (pH 7.4) was incubated with nifedipine (final concentration: 1, 2, 5, 10 and 40 mM) at 371C after 2 min of preincubation without NADPH. The incubation was continued with gentle shaking at 371C for 30 min and the reaction was stopped with ethyl acetate (3 ml). A measure of 50 ml of methanol and 12.5 ml of 20 mM phenytoin (internal standard) were added to each sample. The organic layers were transferred to other vials after centrifugation at 1500 g for 10 min and evaporated to dryness. The residues were dissolved in 200 ml of the mobile phase. A measure of 50 ml were analyzed by high-performance liquid chromatography (HPLC) with a reverse-phase column (Mightysil RP-18 GP250, 4.6 Â 250 mm 2 , Kanto Chemical Industries Ltd, Kyoto, Japan). The column temperature was set at 401C. The mobile phase was composed of 40% acetonitrile (pH 3.0 with perchloric acid) and was delivered at a constant flow rate of 1.2 ml/min. Nifedipine, M-I and phenytoin were detected by a UV detector (Nanospace, SHISEIDO, Tokyo, Japan) with a wavelength at 254 nm. In determining kinetic parameters, nifedipine concentration ranged from all points.
Subjects
Institutional Review Board approval of the study protocol was obtained. In all, 16 healthy male Japanese volunteers participated in this study ( Table 2 ). The subjects gave written informed consent to participate.
A total of 33 healthy volunteers was screened by the genotyping test to find the eight CYP3A5*1/*3 subjects and eight CYP3A5*3/*3 subjects. The genotyping test of CYP3A5 was conducted according to the previous study. 6, 26 All subjects were healthy as assessed by medical history, physical examination, hematologic tests, blood chemistry and urinalysis, and the results of a positive test for hepatitis B and C, human immunodeficiency virus and syphilis.
Eight CYP3A5*1/*3 and eight CYP3A5*3/*3 subjects who showed normal results on routine laboratory tests described above and the negative results of virus tests were selected.
Genotyping Test
Genomic DNA was isolated from peripheral leukocytes using QIAGEN blood kit. The genotypes of each individual at the CYP3A5*3 and CYP3A5*6 alleles were determined using PCR-restriction fragment length polymorphism analysis according to the previous report. 6 For the analysis of the CYP3A5*3 allele, the forward (CYP3A5 6956Fm; 5 0 -CTT TAA AGA GCT CTT TTG TCT CTC A-3 0 ) and reverse (CYP3A5 7155R; 5 0 -CCA GGA AGC CAG ACT TTG AT-3 0 ) primers were used (GenBank accession no. AC005020). For the analysis of the CYP3A5*6 allele, the forward (CYP3A5 14505F; 5 0 -GTG GGT TTC TTG CTG CAT GT-3 0 ) and reverse (CYP3A5 14741R; 5 0 -GCC CAC ATA CTT ATT GAG AG-3 0 ) primers were also created based on the published sequence. These PCR reactions were carried out in 25 ml of solution consisting of 2.5 ml of 10 Â PCR buffer, 0.2 mM of each dNTP, 0.4 mM of each primer, 90 ng of genomic DNA as a template and 1 U of AmpliTaq Gold (Perkin-Elmer, Branchburg, NJ, USA). After initial denaturation at 951C for 10 min, the amplification for the CYP3A5*3 or *6 alleles was performed using 37 cycles of 941C for 30 s, 561C (*3) or 581C (*6) for 30 s and 721C for 30 s, followed by 721C for 5 min for final extension. After PCR amplification, 5 ml of each PCR product was digested for a minimum of 2 h at 371C with 5 U of DdeI before electrophoresis using a 3% agarose gel. CYP3A5*5 and CYP3A5*7 alleles were also determined according to the method of van Schaik et al 26 with some modifications.
Study Design
A single oral dose of 10 mg of nifedipine (Adalat s Bayer, Germany) with 200 ml of water was administered to the subjects at 01000 after overnight fasting. Blood samples (7 ml each) were collected before administration and at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h after administration. During this study, adverse effects were assessed on an ongoing basis as subjects offered information. Blood pressure and pulse rate were measured before administration and at 1, 2, 3, 12 and 24 h after administration. A 12-lead electrocardiogram was recorded before administration and at 2.5 and 24 h after administration. Hematologic tests, blood chemistry and urinalysis were performed before administration and at 24 h after administration.
Grapefruit juice, St John's Wort, alcohol, caffeine-containing beverages, tobacco and exercises were not allowed during the study.
Assays
Blood samples were collected in heparinized tubes and adequately protected from light and centrifuged to obtain serum. The samples were stored frozen at -201C until analyzed. Plasma concentrations of nifedipine and M-I were measured by HPLC as described previously with minor modifications. [27] [28] [29] Briefly, nifedipine and M-I were extracted with dichloromethane/pentane (3 : 7, v/v) and separation of the compounds was achieved using an Inertsil ODS-3 column (3 mM particles, 4.0 Â 100 mm 2 , GL Sciences Inc., Tokyo, Japan). The compounds were detected at a wavelength of 230 nm using a UV detector (SPD-10Avp, SHIMADZU, Tokyo, Japan).
Pharmacokinetic Parameters
The peak plasma concentration (C max ) and the time to reach the C max (T max ) were obtained as measured values. The apparent first-order elimination rate constant (K) of nifedipine was determined by linear regression analysis of the slope of the terminal phase using the last three or four points on the log plasma drug concentration-time curve. The terminal elimination half-life (t 1/2 ) was calculated from the relation t 1/2 ¼ 0.693/K. The area under the plasma concentration-time curve from 0 to 12 h after administra-tion (AUC 0-12 h ) was calculated by the linear trapezoidal method. The area under the drug concentration-time curve from time to infinity (AUC N ) was determined by the linear trapezoidal method with extrapolation to infinity. Clearance (CL/F) was calculated as dose/(AUC N ). The plasma nifedipine/M-I ratio was calculated from the AUC 0-12 h value of nifedipine and M-I.
Data Analysis
The pharmacokinetic parameters and the plasma nifedipine/ M-I ratios were first analyzed by one-way ANOVA. If the overall F ratio was significant, further comparison of the means was performed with the Student's t-test. Statistical analysis of the pharmacodynamic variables of systolic and diastolic blood pressure, and pulse rate made under resting conditions, were performed using ANOVA with repeated measurements. Time was used as a repeated variable. A probability level of Po0.05 was considered to be statistically significant.
